Jazz Pharmaceuticals PLC
(STU:J7Z)
€
101.45
2.25 (2.27%)
Market Cap: 6.25 Bil
Enterprise Value: 9.77 Bil
PE Ratio: 18.82
PB Ratio: 1.80
GF Score: 74/100 Jazz Pharmaceuticals PLC at Bank of America Merrill Lynch Global Healthcare Conference (Virtual) Transcript
Sep 18, 2020 / 03:45PM GMT
Release Date Price:
€116
(-3.33%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
Good day, everybody. My name is Jason Gerberry. I cover Smid cap biotech and specialty pharma at Bank of America. I am pleased to be introducing our next company presenter at the BofA Global Healthcare Conference. I'm pleased to be introducing Jazz Pharmaceuticals and COO, Dan Swisher.
Jazz is known for its lead position in sleep medicines but also has an ever-growing oncology portfolio. So interested to talk about the company's expanding pipeline and on market business.
So Dan, thanks so much for joining us today.
Daniel N. Swisher
Jazz Pharmaceuticals plc - President & COO
Yes. Thanks, Jason, for having us.
Questions & Answers
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research
So maybe we can just jump into Q&A here. And obviously, the company has a substantial blockbuster drug in Xyrem and coming along with that is positives and some negatives. A
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot